Abstract:Abstract BACKGROUND AND AIMS Haemodialysis patients are known to be susceptible to a wide range of early and long-term complications such as chronic inflammation, infections, malnutrition, mineral bone disorders (CKD-MBD) and cardiovascular disease that significantly affect the incidence of mortality.The aim of this study is to assess the presence of traditional risk factors for mortality such as diabetes mellitus or cardiovascular disease on one hand and non-traditional risk factors on the other hand (chronic inflammation, CKD-MBD). METHOD We conducted a single-centre study that included 63 CKD G5D patients (haemodialysis for 1–5 years) followed up for 48 months. All patients have been assessed at baseline, regarding cardiovascular disease (medical history, echocardiography and ECG), we performed using standard methods blood biochemistry, complete blood count and markers of inflammation (CRP, IL-6) and markers of CKD-MBD (sKlotho, iPTH, serum calcium and serum phosphorus). RESULTS After 24 months of follow-up, we found a mortality rate of 22.23%, while after 48 months, the mortality rate was of 50.73%. Baseline plasma IL-6 levels showed a strong statistically significant correlation with sKlotho (r = 0.57, P = 0.001), but no statistically significant correlation with other elements of CKD-MBD was present (serum calcium, serum phosphorus and iPTH). sKlotho showed a positive correlation with haemodialysis efficiency (eKTV) (r = 0.26, P = 0.04)., Decreased levels of sKlotho at baseline correlated significantly with the presence of signs of ischaemia on ECG (190.3 versus 381.57 pg/mL; P = 0.028). Inflammation markers (IL-6 and CRP) showed no statistically significant correlation with any of the markers of cardiovascular disease (presence of vascular calcifications and of left ventricular hypertrophy). The level of iPTH at baseline was significantly lower in the group of patients that survived the following 4 years of haemodialysis (428.08 ± 315.39 versus 666.76 ± 484.55 pg/mL, P = 0.029). In a Cox proportion-hazards regression analysis of predicting factors of mortality, only age and not inflammation markers (IL-6 and CRP) showed a statistically significant correlation with 4-year mortality (P = 0.032). Patients with higher levels of sKlotho showed a decreased risk of mortality, however not statistically significant. We found a higher risk of all-cause mortality after 24 months in patients with diabetes mellitus [OR 6.9, 95% confidence interval (95% CI) 1.6924–28.1469; P = 0.007], and after 48 months in patients with a history of cerebro-vascular disease (OR 21.8571, 95% CI 1.2018–397.5026; P = 0.0371) and with left ventricular hypertrophy (OR 2.7259, 95% CI 0.9596–7.7437; P = 0.0598). CONCLUSION In our study, although the inflammation marker IL-6 showed correlations with features of CKD-MBD, it did not lead to an increased mortality, which was influenced rather by traditional risk factors such as age, diabetes mellitus or history of cardiovascular disease, but also by CKD-MBD (iPTH).

Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients

Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

MO933: are Chronic Inflammation and CKD-MBD Risk Factors of Mortality in Hemodialysis Patients?

Altered monocytic phenotypes are linked with systemic inflammation and may be linked to mortality in dialysis patients

Increased Pretransplant Inflammatory Biomarkers Predict Death With Function After Kidney Transplantation

Inflammatory Syndrome in Patients on Hemodialysis

Inflammation, Malnutrition, and Cardiac Disease as Predictors of Mortality in Hemodialysis Patients

Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?

Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD

Inflammation and cardiovascular risk in dialysis patients

Mortality prediction in stable hemodialysis patients is refined by YKL-40, a 40-kDa glycoprotein associated with inflammation

Pro- and anti-inflammatory factors, vascular stiffness and outcomes in chronic hemodialysis patients

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study

Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function

Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients

Proportions of Proinflammatory Monocytes Are Important Predictors of Mortality Risk in Hemodialysis Patients

Increased Soluble Suppression of Tumorigenicity 2 Level Predicts All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study

Uremic Toxins and Inflammation: Metabolic Pathways Affected in Non-Dialysis-Dependent Stage 5 Chronic Kidney Disease

Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus

Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury